Last reviewed · How we verify
NCT07472036: ENTER
Improving Breast Cancer Screening Uptake Through Tailored Reminder Letters
NA trial testing Tailored reminder letter in Health Behavior in 7,947 participants. Completed in 16 December 2025.
30 September 2024
Quick facts
| Lead sponsor | Universiteit Antwerpen |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | screening |
| Enrollment | 7,947 |
| Start date | 1 April 2024 |
| Primary completion | 30 September 2024 |
| Estimated completion | 16 December 2025 |
| Sites | 2 locations across Belgium |
Drugs / interventions tested
- Tailored reminder letter
Conditions studied
- Health Behavior — all drugs for Health Behavior →
- Breast Cancer Screening — all drugs for Breast Cancer Screening →
- Mammography — all drugs for Mammography →
Sponsor
Universiteit Antwerpen — full company profile →
Who can join
Adults 50 to 69, any sex, with Health Behavior or Breast Cancer Screening. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this trial is to learn whether a culturally and linguistically tailored reminder letter can increase participation in the Flemish Breast Cancer Screening Program among women who previously did not attend screening. The study also examines whether the effect differs between socioeconomic groups. The main questions it aims to answer are: * Does a tailored reminder letter increase participation among previous non-attenders? * Does the effect differ between women with lower and higher socioeconomic status? Researchers compare two groups: * Intervention group: receive the standard invitation letter plus an additional tailored reminder letter. * Control group: receive the standard invitation letter only. Participation in screening within 40 days of the invitation is measured using the program's registry. Participants are women aged 50-69 years who had previously been invited but had never attended screening. The reminder letter is sent as part of routine screening communication, and no additional medical procedures are involved.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07472036
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Health Behavior
Currently open trials in the same condition.
- NCT07466797 — The eHealth Integrated Maternal Physical Activity Programme in Prenatal Care Trial (E-IMPACT) · NA · recruiting
- NCT07248904 — The Effect of a Transtheoretical Model-Based Educational Intervention on First-Year Nursing Students' HPV Knowledge, Hea · NA · recruiting
- NCT07224412 — A Digital Intervention to Promote Preschool Nutrition and Activity: The eHEROs Study · NA · recruiting
- NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
- NCT07226271 — Consumer Perceptions of Alcoholic Beverages · NA · recruiting
Other Universiteit Antwerpen trials
Trials by the same sponsor.
- NCT07407569 — Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After H · Phase 2 · recruiting
- NCT07355101 — Personalized Exercise Coaching to Improve Quality of Life in Pediatric IBD · NA · active not recruiting
- NCT06962579 — The Effect of Personalized Exercise Interventions for the Prevention of Chemotherapy-induced Peripheral Neuropathy · NA · recruiting
- NCT06999473 — Assessment and Treat Neglect Patients With a VR Application · NA · not yet recruiting
- NCT07161531 — Test-retest Reliability of sEMG to Measure Fatigue in Adolescents · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07472036 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universiteit Antwerpen
- Last refreshed: 16 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07472036.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing